

Supplementary Material

Supplementary References

S1. Chen A, Hudesman D, Adhikari S, et al. Covid-19 in immune-mediated inflammatory diseases — case series from new york. *The New England journal of medicine*. 2020;383(1):85-88.

<http://dx.doi.org/10.1056/NEJMc2009567>. doi: 10.1056/NEJMc2009567.

S2. Shahidi-Dadras M, Abdollahimajd F, Ohadi L, et al. COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: A tele-medicine experience. *The Journal of dermatological treatment*. 2020;ahead-of-print(ahead-of-print):1-2. <http://www.tandfonline.com/doi/abs/10.1080/09546634.2020.1789041>. doi: 10.1080/09546634.2020.1789041.

S3. Meca-Lallana V, Aguirre C, Beatrizdel Río, Cardeñoso L, Alarcon T, Vivancos J. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. *Multiple sclerosis and related disorders*. 2020;44:102306.

<http://dx.doi.org/10.1016/j.msard.2020.102306>. doi: 10.1016/j.msard.2020.102306.

S4. Uppal NN, Kello N, Shah HH, et al. De novo ANCA-associated vasculitis With Glomerulonephritis in COVID-19. *Kidney international reports*. 2020;5(11):2079-2083. <http://dx.doi.org/10.1016/j.ekir.2020.08.012>. doi: 10.1016/j.ekir.2020.08.012.

S5. Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H. Newly diagnosed glomerulonephritis during COVID-19 infection undergoing immunosuppression therapy, a case report. *Iranian journal of kidney diseases*. 2020;14(3):239. <https://www.ncbi.nlm.nih.gov/pubmed/32361703>.

S6. Hussein A, AL Khalil K, Bawazir YM. Anti-neutrophilic cytoplasmic antibody (ANCA) vasculitis presented as pulmonary hemorrhage in a positive COVID-19 patient: A case report. *Cureus (Palo Alto, CA)*. 2020. doi: 10.7759/cureus.9643.

S7. Sharmeen S, Elghawy A, Zarlasht F, Yao Q. COVID-19 in rheumatic disease patients on immunosuppressive agents. *Seminars in arthritis and rheumatism*. 2020;50(4):680-686.

<http://dx.doi.org/10.1016/j.semarthrit.2020.05.010>. doi: 10.1016/j.semarthrit.2020.05.010.

S8. Schramm MA, Venhoff N, Wagner D, et al. COVID-19 in a severely immunosuppressed patient with life-threatening eosinophilic granulomatosis with polyangiitis. *Frontiers in immunology*. 2020; 11:2086.

<https://search.proquest.com/docview/2446991861>. doi: 10.3389/fimmu.2020.02086.

S9. Leipe J, Wilke EL, Ebert MP, Teufel A, Reindl W. Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. *Seminars in arthritis and rheumatism*. 2020;50(5):1087-1088.

<http://dx.doi.org/10.1016/j.semarthrit.2020.06.013>. doi: 10.1016/j.semarthrit.2020.06.013.

S10. Shenavandeh S, Sefidbakht S, Iranpour P, et al. COVID-19 and granulomatosis with polyangiitis (GPA): A diagnostic challenge. *Rheumatology (Oxford, England)*. 2020;59(8):2170-2171.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337806/>. doi: 10.1093/rheumatology/keaa326.

S11. Fallet B, Kyburz D, Walker UA. Mild course of coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B-cells due to treatment with rituximab. *Arthritis & rheumatology (Hoboken, N.J.)*. 2020. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245853/>. doi: 10.1002/art.41380.

S12. Suárez-Díaz S, Morán-Castaño C, Coto-Hernández R, Mozo-Avellaneda L, Suárez-Cuervo C, Caminal-Montero L. Mild COVID-19 in ANCA-associated vasculitis treated with rituximab. *Annals of the rheumatic diseases*. 2020:annrheumdis-218246. <https://search.proquest.com/docview/2431826223>. doi: 10.1136/annrheumdis-2020-218246.

Methods

We prospectively followed six patients with AAV from our center with COVID-19 to determine demographics and outcomes. Additionally, we conducted a literature search with assistance of a medical librarian via Pubmed-MEDLINE employing varying combinations of terms including 'ANCA', 'vasculitis', 'anti-neutrophil cytoplasmic antibody', 'COVID-19', 'Corona virus 2019', 'SARS-CoV-2', since December 2019 to search for cases of AAV with COVID-19 infection, to aid in combined analysis of cases.